LRMR
HEALTHCARELarimar Therapeutics Inc
$4.15+0.14 (+3.49%)PRE
Live · NASDAQ · May 8, Close
AI Insight
What's Moving LRMR Today?
No stock-specific AI insight has been generated for LRMR yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.73$6.42
$4.15
Fundamentals
Market Cap$431M
P/E Ratio—
EPS$-2.27
Dividend Yield—
Dividend / Share—
ROE-1.3%
Profit Margin—
Debt / Equity—
Trading
Volume2.4M
Avg Volume (10D)—
Shares Outstanding103.9M
LRMR News
20 articles- Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s AtaxiaYahoo Finance·Apr 30, 2026
- Wedbush Raises its Price Target on Larimar Therapeutics (LRMR) to $13Yahoo Finance·Mar 27, 2026
- Larimar: Q4 Earnings SnapshotYahoo Finance·Mar 19, 2026
- Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial ResultsYahoo Finance·Mar 19, 2026
- LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month?Yahoo Finance·Mar 6, 2026
- Larimar Therapeutics to Participate in Upcoming Investor Conferences in MarchYahoo Finance·Mar 4, 2026
- Larimar Therapeutics price target raised to $12 from $11 at WedbushYahoo Finance·Mar 4, 2026
- Larimar Therapeutics (LRMR) Is Up 78.8% After Breakthrough Nod And $100M Raise Has The Bull Case Changed?Yahoo Finance·Feb 28, 2026
- Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public OfferingYahoo Finance·Feb 26, 2026
- Larimar Therapeutics Announces Proposed $75 Million Underwritten Public OfferingYahoo Finance·Feb 25, 2026
- BC-Most Active StocksYahoo Finance·Feb 25, 2026
- Larimar Therapeutics' Friedreich's Ataxia Therapy Receives FDA Breakthrough Status; Shares RiseYahoo Finance·Feb 24, 2026
- Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026Yahoo Finance·Feb 24, 2026
- Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceYahoo Finance·Dec 18, 2025
- Here's Why We're Watching Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn SituationYahoo Finance·Nov 14, 2025
- Larimar: Q3 Earnings SnapshotYahoo Finance·Nov 5, 2025
- Larimar Therapeutics Reports Third Quarter 2025 Financial ResultsYahoo Finance·Nov 5, 2025
- Will Positive Nomlabofusp Study Results Alter Larimar Therapeutics' (LRMR) Standing in Rare Disease Treatment?Yahoo Finance·Oct 4, 2025
- Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s AtaxiaYahoo Finance·Sep 29, 2025
- Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich’s AtaxiaYahoo Finance·Sep 28, 2025
All 20 articles loaded
Price Data
Open$4.23
Previous Close$4.01
Day High$4.29
Day Low$4.00
52 Week High$6.42
52 Week Low$1.73
52-Week Range
$1.73$6.42
$4.15
Fundamentals
Market Cap$431M
P/E Ratio—
EPS$-2.27
Dividend Yield—
Dividend / Share—
ROE-1.3%
Profit Margin—
Debt / Equity—
Trading
Volume2.4M
Avg Volume (10D)—
Shares Outstanding103.9M
About Larimar Therapeutics Inc
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, is focused on developing treatments for rare diseases. The company is headquartered in Bala Cynwyd, Pennsylvania.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—